相关实验视频

Updated: Jun 22, 2025

Author Spotlight: Exploring the Mysteries of Sichuan's Herbal Medicine in Chinese Medicine Research

Author Spotlight: Exploring the Mysteries of Sichuan's Herbal Medicine in Chinese Medicine Research

Published on: March 1, 2024

口服的histidine会影响肠道微生物群和MAIT细胞,改善2型糖尿病患者的血糖控制

Moritz V Warmbrunn^1,2,3, Ilias Attaye^1,2,3, Judith Aron-Wisnewsky^4,5

¹Department of Internal and Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

|July 4, 2024

概括

口服西提丁补充剂改善了2型糖尿病患者的血糖控制. 这种必不可少的氨基酸还增加了有益的MAIT细胞,可能是通过肠道细菌和表观遗传变化.

科学领域:

代谢研究的研究.
免疫学免疫学免疫学
微生物组研究的研究.

背景情况:

氨基酸,包括histidine,通过宿主细胞和肠道细菌代谢影响宿主代谢.
口服歇斯蒂丁补充剂已经证明了代谢益处.
饮食中的histidine在血糖控制中的作用需要进一步调查.

研究的目的:

为了研究饮食中西丁对2型糖尿病患者和健康对照者的血糖控制的影响.
探索肠道微生物组对胺代谢的贡献及其对宿主健康的影响.
评估histidine补充剂,免疫细胞概况,表观遗传修饰和肠道微生物群组成之间的关系.

主要方法:

一个病例控制的并行临床干预研究,涉及口服希斯蒂丁补充剂七周.
两周后抗生素诱导的微生物群枯竭,以评估微生物的贡献.
评估血糖控制标记物,周围血液单核细胞 (PBMC) 免疫表型,DNA甲基化和便肠道微生物群组成.

主要成果:

丁补充剂改善了几种血糖控制标志物,特别是降低了食后葡萄糖水平.
经过两周的histidine摄入后,观察到粘膜相关的不变T细胞 (MAIT) 的显著增加.
MAIT细胞的增加与肠道微生物通路的改变 (例如, рибофлавин生物合成) 和SLC7A5基因的表观遗传变化相关.

结论:

口服的伊斯蒂丁显示出改善血糖控制的潜力,部分是通过调节MAIT细胞群.
肠道微生物组和表观遗传变化,特别是涉及SLC7A5的变化,似乎调解了histidine的作用.
对MAIT细胞中flavin生物合成和SLC7A5的进一步研究可能为血糖控制策略提供新的途径.

关键词:

微生物组是一个微生物组.糖尿病糖尿病患者糖尿病患者这就是histidine.胰岛素耐药性是一种胰岛素耐药性.单细胞 (Monocytes) 是一种单细胞.

更多相关视频

Cultivation of Heligmosomoides Polygyrus: An Immunomodulatory Nematode Parasite and its Secreted Products

Cultivation of Heligmosomoides Polygyrus: An Immunomodulatory Nematode Parasite and its Secreted Products

Published on: April 6, 2015

Murine Fecal Isolation and Microbiota Transplantation

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

相关概念视频

What is Monogastric Digestion?

What is Monogastric Digestion?

The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Hormones Regulating Blood Glucose

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...